Urinary Incontinence Surgery — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Urinary incontinence surgery encompasses a group of surgical procedures aimed at curing or substantially reducing stress urinary incontinence (SUI) — the involuntary leakage of urine during physical exertion, coughing, sneezing, or laughing — and mixed urinary incontinence in women where the stress component predominates and conservative management has been inadequate. The principal surgical options are: midurethral slings — tension-free vaginal tape (TVT), which follows a retropubic path from the vagina to the suprapubic skin; and transobturator tape (TOT/TVT-O), which follows a lateral path through the obturator foramen — both of which support the mid-urethra with a synthetic polypropylene mesh strip, restoring the backboard support that prevents urethral descent during increases in intra-abdominal pressure; and Burch colposuspension, an open or laparoscopic procedure that elevates and suspends the bladder neck and proximal urethra by suturing the paravaginal fascia to Cooper's ligament on the posterior aspect of the pubic bone. Autologous rectus fascial sling — using the patient's own fascia from the lower abdominal wall — is an effective non-mesh alternative with excellent long-term durability, recommended particularly for women who cannot or will not consent to synthetic mesh, those with prior mesh complications, or women with intrinsic sphincter deficiency in whom a more compressive sling support is required. Regulatory guidance in the UK (NHS England 2018 pause) and Australia mandates stringent pre-operative counselling and specialist surgical expertise for any mesh-based incontinence procedure.

Surgical intervention is appropriate for women with stress urinary incontinence confirmed on clinical assessment and urodynamic testing — demonstrating urodynamic stress incontinence (USI) on bladder filling cystometry — who have undergone and failed an adequate trial of supervised conservative management for a minimum of 3-6 months. Conservative treatment includes a structured pelvic floor muscle training (PFMT) programme supervised by a specialist physiotherapist — completing a minimum of 3 months of at least 8 contractions three times daily as recommended by NICE — bladder retraining for any associated urgency, weight loss where BMI exceeds 30 (which reduces intra-abdominal pressure), smoking cessation, and an appropriate vaginal pessary trial where applicable. Urodynamic assessment is strongly recommended before surgery to confirm the diagnosis of stress incontinence, quantify detrusor overactivity (if present), assess bladder capacity and compliance, and measure leak-point pressure — a low Valsalva leak point pressure below 60 cmH2O indicating intrinsic sphincter deficiency influences the choice between sling types. Women who present with urgency predominant mixed incontinence, severe pelvic organ prolapse requiring concurrent repair, neurological bladder dysfunction, or a history of prior incontinence surgery require specialist multidisciplinary urogynaecology or urology assessment before any surgical intervention.

Tension-Free Vaginal Tape (TVT) procedure: performed under general, spinal, or local plus sedation anaesthesia as a day case or overnight stay. With the patient in the lithotomy position, a 1.5 cm anterior vaginal wall incision is made at the mid-urethra level, and the periurethral vaginal space is developed with sharp and blunt dissection bilaterally. Two 5 mm skin incisions are made suprapubically, one either side of the midline. The TVT curved introducer loaded with the mesh tape is inserted through the vaginal incision and advanced blindly through the retropubic space — lateral to the urethra — emerging through each suprapubic skin incision in turn. Correct positioning is confirmed by cystoscopy (visualising the needle passing through the retropubic space without bladder injury at every passage, mandatory at both sides). The mesh tape is tension-free adjusted with the patient awake performing a cough test, ensuring no urethral kinking. The plastic sheaths are removed and the vaginal and suprapubic incisions closed. Transobturator Tape (TOT/TVT-O): the mesh tape is passed from a small vaginal incision laterally through the obturator foramen in an inside-out (TVT-O) or outside-in (TOT) manner, emerging through two small groin skin incisions at the inner thigh crease. This route avoids the retropubic space, greatly reducing the bladder perforation risk but carrying a risk of groin pain from obturator nerve irritation. Burch colposuspension: performed laparoscopically under general anaesthesia. The retropubic space (cave of Retzius) is entered; the paravaginal fascia at the level of the bladder neck and proximal urethra is sutured to Cooper's ligament bilaterally with non-absorbable sutures under direct visualisation, elevating and supporting the urethra.

Midurethral sling procedures achieve subjective cure — defined as no leakage on self-report and satisfaction with continence status — in 80-90% of women at 1-5 years, representing the highest efficacy rates of any available treatment for stress urinary incontinence. Objective cure rates, defined by negative cough stress test or pad test, are 70-80% at 5 years. These outcomes are substantially superior to conservative management alone (40-60% improvement), pelvic floor physiotherapy alone (40-60% symptom improvement but rarely cure), and urethral bulking agents (25-40% cure). Burch colposuspension achieves equivalent long-term cure rates to midurethral slings in randomised controlled trials (VALOR trial, Cochrane systematic review) via a non-mesh approach, making it a preferred alternative for patients who decline mesh. Autologous fascial sling achieves similar long-term cure rates of 80-90% at 5 years with excellent durability and is widely recommended as the reference non-mesh standard. Successful incontinence surgery significantly improves quality of life, sexual confidence, physical activity participation, social engagement, and psychological wellbeing, with validated improvements in the ICIQ-UI Short Form, Urogenital Distress Inventory, and EQ-5D scores at 12 months post-operatively.

TVT-specific intraoperative risks include bladder perforation during the needle passes through the retropubic space, occurring in 3-5% of procedures; mandatory bilateral cystoscopy after every TVT needle passage identifies and confirms perforation, allowing the needle to be repositioned and the procedure safely completed without long-term consequence if promptly identified. Voiding dysfunction — difficulty initiating or sustaining urinary flow — occurs in 5-10% of patients in the immediate post-operative period as a consequence of the tape being tensioned slightly too tightly; most cases resolve spontaneously within 2-6 weeks, but 1-2% may require tape division under local anaesthesia. Mesh-related complications — including tape erosion into the vaginal wall (appearing as a palpable rough exposed mesh edge on examination, occurring in 1-4% of cases), urethral erosion (rare, under 0.5%), and chronic pelvic or groin pain syndrome — represent the most serious concerns associated with synthetic mesh incontinence procedures and have driven regulatory scrutiny worldwide. De novo urgency incontinence (new bladder overactivity after surgery) occurs in 10-15% of women and is treated with anticholinergic or beta-3 agonist medication. Failed or recurrent incontinence after primary surgery occurs in 15-20% at 5-10 years and requires further assessment and potentially revision surgery, bulking agents, or artificial urinary sphincter.

Following day-case TVT or TOT procedures, most women are discharged after a successful trial of voiding — confirming a post-void residual below 150 mL by bedside ultrasound. Women who cannot void adequately are discharged with a urethral catheter or taught clean intermittent self-catheterisation (CISC) and return for a voiding trial in 5-7 days. The vaginal incision heals within 2-3 weeks without suture removal as absorbable sutures are used. Light activities including personal care and gentle walking may resume the following day. More strenuous activities — heavy lifting over 5 kg, vigorous exercise, swimming, sexual intercourse — are deferred for 4-6 weeks to protect the mesh during tissue ingrowth and to allow vaginal healing. Pelvic floor exercises are continued post-operatively as an adjunct to surgical outcome, though the primary continence mechanism is provided by the mesh support. A follow-up assessment at 6-8 weeks evaluates continence outcome, confirms wound healing, assesses any residual voiding symptoms, and provides an opportunity for further patient education. Women must be informed to report any new vaginal discharge, pain, or the sensation of a rough or prominent area in the vagina, which may indicate mesh exposure requiring specialist review. Long-term surveillance with annual assessment in specialist urogynaecology or continence clinics is advocated for mesh-implanted patients.